We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

New ‘powerful’ lab test will help researchers explore blood cancer

Mission Bio has debuted a new laboratory test that enables researchers to simultaneously detect alterations in the genetic code and changes in genetic activity — starting with whether a gene is turned on or off — within the same cell. The test, dubbed the Tapestri...

Case: Growth on pancreas shows estrogen link to pancreatic cancer

Changes in how cells respond to the hormone estrogen may underlie the development of certain forms of pancreatic cancer. That’s according to findings from testing done on a growth removed from the pancreas of a woman in Japan who had given birth several months before....

Glioma trial of intranasal therapy NEO100 fills all patient slots

Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows the release of positive interim data suggesting the experimental treatment, which uses a compound...

WHO grants nonproprietary name to ovarian cancer cell therapy

A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The therapy, which is already in clinical testing, will now carry the INN liraltagene...
Latest Data

Latest Publications

Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis

Front Immunol. 2025 Oct 30;16:1669878. doi: 10.3389/fimmu.2025.1669878. eCollection 2025. ABSTRACT...

The challenge of non-transplant eligible, newly diagnosed multiple myeloma

Leuk Lymphoma. 2025 Oct;66(10):1767-1777. doi: 10.1080/10428194.2025.2513676. Epub 2025 Jun 3....

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

J Natl Cancer Inst. 2025 Nov 9:djaf326. doi: 10.1093/jnci/djaf326. Online ahead of print. ABSTRACT...

Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review

Chin Med J (Engl). 2025 Oct 31. doi: 10.1097/CM9.0000000000003832. Online ahead of print. NO...

Email

info@myeloma360.com